Group members

I am a Molecular and Cellular Biologist with a PhD in Life Sciences from FCT-Universidade Nova de Lisboa/Imperial College London, and now funded by a Fellowship from the Kay Kendall Leukaemia Fund. I have always been fascinated by the mechanisms of transcriptional regulation that orchestrate gene expression and the consequent impact on cell-type specification. I study the role of MYB-enhancer mutations in oncogene activation using T-cell Acute Lymphoblastic Leukaemia as a cancer model.

Funded by CRUK. I studied a BSc Biotechnology (2010), an MSc Immunology (2011), and then completed a PhD in Biomedicine in 2016. During my PhD, I was involved in the discovery of new biomarkers for stroke diagnosis through proteomic approaches. I currently research the generation of a functional map of the oncoprotein c-MYC aiming to discover novel protein-protein interactions that drive MYC oncogenicity in T-cell acute lymphoblastic leukemia (T-ALL) using proteomic and molecular techniques.

I am postdoctoral fellow working on DECOD-Ag, a collaboration between UCL (Mansour and Quezada Labs), Achilles Therapeutics, Crick, Weizmann Institute of Science and Denmark Technical University, and funded by EU Horizon 2020. This aims to develop a revolutionary platform for profiling cancer immunogenic neoantigens, combining an array of science-enabled technologies to decipher the therapeutic potential of neoantigens to support development of innovative personalised cancer immunotherapies.

I did my PhD at Newcastle University on the molecular characterisation of B-cell precursor ALL with IGH rearrangement, using patient derived xenograft models and RNA sequencing. At the Mansour Lab, I work on the drug response profiling of relapse/refractory ALL and AML under REVEALL, a clinical trial co-funded by CRUK and Children with Cancer UK. I make use of a co-culture system that mimics the microenvironment of bone marrow to achieve more accurate predictions of drug responses.

I'm a bioinformatician with a focus in computational genomics of Leukaemia. I completed my PhD at The Chinese University of Hong Kong, where I transitioned from cell culture studies to genome assembly and comparative genomics of insects using third-generation sequencing technology. At the Mansour lab I focus on cancer genomics and epigenetics in Leukaemia. My primary role involves identifying novel mutations in T-cell Acute Lymphoblastic Leukemia (T-ALL) through advanced sequencing techniques.

I am a CRUK-funded Clinician Scientist and Honorary Consultant in Paediatric Haematology at Great Ormond Street Hospital for Children. My PhD at Imperial College explored leukaemogenesis in Down syndrome. I currently research the genetic mechanisms that drive resistance in childhood leukaemia, particularly T-acute lymphoblastic leukaemia. My techniques include next generation sequencing and CRISPR genome-wide screening to identify aberrant pathways that could be targeted with novel agents.

I am a Kay Kendall-funded clinical PhD student and haematology trainee in North Central London. During my CRUK-funded pre-doctoral fellowship I explored a novel potential therapeutic target for T-acute lymphoblastic leukaemia and I am building upon that work for my PhD. I am interested in dissecting the biology of leukaemia and translating this into new treatment strategies. I look forward to acquiring some of the many scientific skill sets that the Mansour group members have to offer.

I gained my degree in Saudi Arabia and an MSc Cell & Gene Therapy at UCL, where I explored the role of cellular senescence as a potential mediator of chronic myeloid leukaemia treatment resistance. My PhD (funded by the Saudi Cultural Bureau) focuses on acute myeloid leukaemia resistance mechanisms. I use clinical samples to examine the genomic and transcriptomic aberrations in coding & non-coding genome of patients with primary chemoresistant AML, and further follow-up with functional studies.

I gained my BSc in 2019 and an MSc in Biomedical Sciences at UCL in 2021. I characterised a novel, multifunctional mechanism of glycolytic inhibitor 4-MU in Neuroblastoma metabolism as part of my UCL research project. I became a Research Technician at the National Heart and Lung Institute, Imperial College London, where I researched the molecular mechanisms of senescence in Chronic Obstructive Pulmonary Disease. My PhD concerns the STIL-TAL1 fusion gene in T-cell acute lymphoblastic leukaemia.

I am funded by the CRUK City of London Centre. I interrupted my clinical training to study a BMSc Cardiovascular & Diabetes Medicine, where I modelled the pro-inflammatory impacts of recurrent hypoglycaemia in bone marrow derived macrophages. I currently research CCR9-directed targeted therapy for T-cell Acute Lymphoblastic Leukaemia. I use molecular and computational techniques inc. genome-wide CRISPR screening and RNA sequencing analyses to understand the regulation of this therapeutic target.

I am a LIDo funded PhD student working on the creation of a universal CAR-T cell product. I gained an MRes Cancer Biology from Imperial College London, completing independent projects at The Institute of Cancer Research and the Peter MacCallum Cancer Centre. I then became a research assistant at Imperial, optimising RNA vaccine technology for equitable access to vaccines. During the COVID pandemic, I was involved in a first in person clinical trial of a self-amplifying RNA COVID vaccine.